Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Blood-based biomarkers for Alzheimer's disease: towards clinical implementation
CE Teunissen, IMW Verberk, EH Thijssen… - The Lancet …, 2022 - thelancet.com
For many years, blood-based biomarkers for Alzheimer's disease seemed unattainable, but
recent results have shown that they could become a reality. Convincing data generated with …
recent results have shown that they could become a reality. Convincing data generated with …
Alzheimer's disease
In this Seminar, we highlight the main developments in the field of Alzheimer's disease. The
most recent data indicate that, by 2050, the prevalence of dementia will double in Europe …
most recent data indicate that, by 2050, the prevalence of dementia will double in Europe …
[HTML][HTML] The China alzheimer report 2022
R Ren, J Qi, S Lin, X Liu, P Yin, Z Wang, R Tang… - General …, 2022 - ncbi.nlm.nih.gov
China's population has rapidly aged over the recent decades of social and economic
development as neurodegenerative disorders have proliferated, especially Alzheimer's …
development as neurodegenerative disorders have proliferated, especially Alzheimer's …
Recent advancements in pathogenesis, diagnostics and treatment of Alzheimer's disease
Background: The only conclusive way to diagnose Alzheimer's is to carry out brain autopsy
of the patient's brain tissue and ascertain whether the subject had Alzheimer's or any other …
of the patient's brain tissue and ascertain whether the subject had Alzheimer's or any other …
Combination of plasma amyloid beta(1-42/1-40) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology
IMW Verberk, E Thijssen, J Koelewijn, K Mauroo… - Alzheimer's research & …, 2020 - Springer
Background Blood-based biomarkers for Alzheimer's disease (AD) might facilitate
identification of participants for clinical trials targeting amyloid beta (Abeta) accumulation …
identification of participants for clinical trials targeting amyloid beta (Abeta) accumulation …
Early-onset Alzheimer's disease: what is missing in research?
Abstract Purpose of Review Early-onset Alzheimer's disease (EOAD), defined as
Alzheimer's disease (AD) occurring before age 65, is significantly less well studied than the …
Alzheimer's disease (AD) occurring before age 65, is significantly less well studied than the …
Opportunities and challenges of alpha-synuclein as a potential biomarker for Parkinson's disease and other synucleinopathies
Abstract Parkinson's disease (PD), the second most common progressive
neurodegenerative disease, develops and progresses for 10–15 years before the clinical …
neurodegenerative disease, develops and progresses for 10–15 years before the clinical …
The role of NADPH oxidases and oxidative stress in neurodegenerative disorders
A Tarafdar, G Pula - International journal of molecular sciences, 2018 - mdpi.com
For a number of years, nicotinamide adenine dinucleotide phosphate (NADPH) oxidases
(NOX) was synonymous with NOX2/gp91phox and was considered to be a peculiarity of …
(NOX) was synonymous with NOX2/gp91phox and was considered to be a peculiarity of …
Plasma amyloid as prescreener for the earliest A lzheimer pathological changes
IMW Verberk, RE Slot, SCJ Verfaillie… - Annals of …, 2018 - Wiley Online Library
Objective We investigated the association of plasma amyloid beta (Abeta) 40, Abeta42, and
total tau (tTau) with the presence of Alzheimer pathological changes in cognitively normal …
total tau (tTau) with the presence of Alzheimer pathological changes in cognitively normal …
Artificial intelligence–coupled plasmonic infrared sensor for detection of structural protein biomarkers in neurodegenerative diseases
Diagnosis of neurodegenerative disorders (NDDs) including Parkinson's disease and
Alzheimer's disease is challenging owing to the lack of tools to detect preclinical biomarkers …
Alzheimer's disease is challenging owing to the lack of tools to detect preclinical biomarkers …